Two Companies Join Forces to Test Stem Cell Therapy Combined With Immune-Modulating Drug for Type 1 Diabetes

Zurich-based NewcelX and Eledon Pharmaceuticals of Irvine, California have announced a research collaboration to test whether combining two therapies might work better than either one alone for type 1 diabetes.

The partnership pairs NewcelX's NCEL-101—a stem cell-derived therapy designed to replace the insulin-producing beta cells destroyed by autoimmunity—with Eledon's tegoprubart, a monoclonal antibody meant to quiet the immune response that damages those cells. The goal is to evaluate whether this combination could offer a more durable and potentially functional cure for the disease.

NCEL-101 is built on a human pluripotent stem cell platform. Rather than targeting a single molecular pathway in the body, it aims to restore insulin production by delivering functional insulin-producing cells directly. The therapy is designed to be manufactured at scale and used off-the-shelf—meaning it could theoretically be given to many patients without requiring individual customization.

Tegoprubart works by binding to CD40 ligand (CD40L), a molecule involved in immune activation. By blocking the interaction between CD40L and CD40 on antigen-presenting cells, the drug is designed to suppress the T-cell-mediated immune response that drives type 1 diabetes. Eledon has already gathered clinical data on tegoprubart in over 100 patients receiving kidney, heart, and diabetes-related transplants under FDA-cleared investigational protocols.

Type 1 diabetes develops when the immune system mistakenly attacks and destroys the pancreas's beta cells, which normally produce insulin. Simply replacing those cells is not enough if the immune attack continues. That's the logic behind pairing cell replacement with immune modulation.

By combining a cell therapy with an immune-dampening agent, researchers hypothesize they might create conditions where transplanted or replacement insulin-producing cells can survive and function long-term, potentially offering a more lasting treatment benefit than cell therapy or immune therapy alone.

This is structured as a research collaboration rather than a traditional licensing deal, and no financial terms were disclosed. The partnership is in its evaluation phase—meaning researchers will now study whether the combination approach is viable in preclinical and potentially early clinical settings before any larger trials might be considered.

While the goal is ambitious—a durable, functionally curative approach—it is important to note that this work is still in early stages of development.

Origin: allsci.com (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.